HCV Program Progress and Clinical Data The BEM/RZR combination demonstrated impressive efficacy in Phase 2 trials, achieving a 98% sustained virologic response at 12 weeks post-treatment (SVR12) in ...
The HCV program, however, reported encouraging Phase II clinical trial results and anticipates the U.S. market for their HCV drug to reach $1.5 billion in net sales. 3rd party Ad. Not an offer or ...
BOSTON, June 24, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral ...
“Nevertheless, these findings highlight the importance of treatment adherence, regular follow-up, and targeted prevention in order to reach the WHO [World Health Organization] HCV elimination goals,” ...
Australian-based Benitec Biopharma has announced the execution of an agreement to acquire the US-based RNA interference (RNAi) therapeutics company Tacere Therapeutics, Inc. (Tacere). Tacere is a ...
SAN DIEGO, Oct. 2, 2012 /PRNewswire/ -- Aethlon Medical, Inc. (OTCBB: AEMD), the pioneer in developing selective therapeutic filtration devices to address infectious disease, cancer and other ...
On-site hepatitis C virus testing and treatment with peer support at opioid treatment programs boosts access to curative ...
The findings of this study suggest that a community-based point-of-care hepatitis C virus (HCV) RNA testing program was feasible and was associated with a high percentage of same-day treatment for ...
Atea Pharmaceuticals (NASDAQ:AVIR) presented its Q2 2025 corporate update on August 7, highlighting significant progress in its hepatitis C virus (HCV) treatment program and providing insights into ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results